EKR Therapeutics Overview

  • Year Founded
  • 2006

Year Founded

  • Status
  • Acquired/​Merged

  • Latest Deal Type
  • M&A

  • Latest Deal Amount
  • $150M

EKR Therapeutics General Information

Description

Developer of prescription products intended to serve the needs of the acute-care hospital setting. The company's products support the life of cancer patients, offer short-term treatment of hypertension and management of various AMI related conditions, enabling patients to get access to preferred treatment at a cost effective manner.

Contact Information

Website
www.ekrtx.com
Ownership Status
Acquired/Merged
Financing Status
Formerly VC-backed
Corporate Office
  • Third Floor
  • Bedminster Township
  • NJ 07921
  • United States
+1 (877) 000-0000
Primary Industry
Pharmaceuticals
Other Industries
Therapeutic Devices
Acquirer
Chiesi USA
Vertical(s)
Life Sciences, Oncology
Corporate Office
  • Third Floor
  • Bedminster Township
  • NJ 07921
  • United States
+1 (877) 000-0000

Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

EKR Therapeutics Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
5. Merger/Acquisition 27-Jun-2012 $150M 00000 00000 Completed Generating Revenue
4. Later Stage VC (Series D) 10-Mar-2008 00000 00000 Completed Startup
3. Later Stage VC (Series C) 22-Aug-2007 000.00 000.00 Completed Startup
2. Early Stage VC (Series B) 15-Nov-2006 $7.33M $7.33M Completed Startup
1. Early Stage VC (Series A) 27-Jun-2006 Completed Startup
To view EKR Therapeutics’s complete valuation and funding history, request access »

EKR Therapeutics Patents

  • 38

    Total Documents Applications and Grants

  • 000

    Total Patents Families

  • 20

    Granted

  • 1

    Pending

  • 000

    Expiring in next 12 mo

EKR Therapeutics Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
US-8455524-B2 Methods of treatment with pre-mixed, ready-to-use pharmaceutical compositions Active 18-Apr-2006 000000000 00
EP-2018152-A2 Pre-mixed, ready-to-use pharmaceutical compositions Inactive 18-Apr-2006 000000000
US-10758616-B2 Pre-mixed, ready-to-use pharmaceutical compositions Active 18-Apr-2006 00000000 00
US-7659290-B2 Of nicardipine or its salts; use treating hypertension; storage stability; making injectable formulations by filling container with premix, adjusting ph and diluting Active 18-Apr-2006 000000000 00
US-20140206643-A1 Pre-mixed, ready-to-use iv bolus nicardipine compositions and methods of use Active 18-Apr-2006 A61K47/02 0
To view EKR Therapeutics’s complete patent history, request access »

EKR Therapeutics Former Investors (11)

Investor Name Investor Type Holding Investor Since Participating Rounds
Canterbury Capital (South Carolina) Venture Capital Minority 000 0000 000000 0
Commerce Health Ventures Venture Capital Minority 000 0000 000000 0
ESP Equity Partners PE/Buyout Minority 000 0000 000000 0
Garden State Life Sciences Venture Fund Venture Capital Minority 000 0000 000000 0
LLR Partners Growth/Expansion Minority 000 0000 000000 0
You’re viewing 5 of 11 investors. Get the full list »

Ready to get started?

Request a free trial

EKR Therapeutics FAQs

  • When was EKR Therapeutics founded?

    EKR Therapeutics was founded in 2006.

  • Who is the founder of EKR Therapeutics?

    Howard Weisman and Douglas Sheldon are the founders of EKR Therapeutics.

  • Where is EKR Therapeutics headquartered?

    EKR Therapeutics is headquartered in NJ.

  • What industry is EKR Therapeutics in?

    EKR Therapeutics’s primary industry is Pharmaceuticals.

  • Is EKR Therapeutics a private or public company?

    EKR Therapeutics is a Private company.

  • What is the current valuation of EKR Therapeutics?

    The current valuation of EKR Therapeutics is 00000.

  • What is EKR Therapeutics’s current revenue?

    The current revenue for EKR Therapeutics is 000000.

  • How much funding has EKR Therapeutics raised over time?

    EKR Therapeutics has raised $151M.

  • Who are EKR Therapeutics’s investors?

    Canterbury Capital (South Carolina), Commerce Health Ventures, ESP Equity Partners, Garden State Life Sciences Venture Fund, and LLR Partners are 5 of 11 investors who have invested in EKR Therapeutics.

  • When was EKR Therapeutics acquired?

    EKR Therapeutics was acquired on 27-Jun-2012.

  • Who acquired EKR Therapeutics?

    EKR Therapeutics was acquired by Chiesi USA.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read blog »

  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process »